Managers / Q4 2025 · view latest →
BIOS Capital Management, LP
CIK 0001813845 · 1751 RIVER RUN, SUITE 400, FORT WORTH, TX, 76107 · 817-984-9197
Summary
Bios Capital Management, LP reported $83M in U.S.-listed holdings across 9 positions for Q4 2025.
The portfolio is heavily concentrated: ACTU alone accounts for 63.7% of reported value.
Compared with Q3 2025, the fund opened 1 new position and exited 1.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- Common Stock · 100.0% · $83M
Quarter-over-Quarter Changes full breakdown →
vs Q3 2025 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| INABIN8BIO INC | NEW | +253.4K | 253.4K | +$592,996 | $592,996 |
| INABEURIN8BIO INC | SOLD OUT | −286.7K | 0 | −$622,061 | $0 |
| LTRNLANTERN PHARMA INC | HELD | −6.2K | 1.01M | −$1M | $3M |
| ACTUACTUATE THERAPEUTICS INC | HELD | +0 | 10.05M | −$6M | $62M |
| IRDOPUS GENETICS INC | HELD | +0 | 3.68M | +$810,354 | $7M |
| RNTXREIN THERAPEUTICS INC | HELD | +0 | 1.69M | +$16,907 | $2M |
| CGTXCOGNITION THERAPEUTICS INC | HELD | +0 | 6.00M | +$1 | $8M |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q4 2025
| # | Issuer | Class | % Portfolio | Value ↓ | Shares |
|---|---|---|---|---|---|
| 1 | ACTUACTUATE THERAPEUTICS INChistory → | COM | 74.44% | $62M | 10.05M |
| 2 | CGTXCOGNITION THERAPEUTICS INChistory → | COM | 9.80% | $8M | 6.00M |
| 3 | IRDOPUS GENETICS INChistory → | COM | 8.96% | $7M | 3.68M |
| 4 | LTRNLANTERN PHARMA INChistory → | COM | 3.70% | $3M | 1.01M |
| 5 | RNTXREIN THERAPEUTICS INChistory → | COM NEW | 2.37% | $2M | 1.69M |
| 6 | INABIN8BIO INC | COM NEW | 0.72% | $592,996 | 253.4K |
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q1 2026 | $53M | 10 | May 13, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q4 2025 | $83M | 9 | Feb 13, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q3 2025 | $89M | 9 | Nov 12, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q2 2025 | $73M | 9 | Aug 12, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q1 2025 | $79M | 9 | May 14, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q4 2024 | $94M | 9 | Feb 18, 2025 | RESTATEMENT | changes · EDGAR ↗ |
Other Included Managers
This filing reports holdings on behalf of 1 additional manager.
- Steelhead Capital Management, LLC028-24869
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.